AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
mercaptamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| aptamers, classical and mirror ones | 768 | 60-23-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,ALK,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,IKBKB,IRAK1,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 60 | |||
| kinase-selectivity-class | AKT3,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK4,CHEK1,CLK2,DYRK1B,EIF2AK3,GAK,IRAK4,MAP3K7,MAP4K1,MAP4K3,MARK4,MELK,PAK4,PDPK1,PRKCD,SIK2,SIK3,STK33,SYK,TTK,ULK2 | 26 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 1997 | EMA | ||
| Aug. 15, 1994 | FDA | MYLAN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye irritation | 131.52 | 53.89 | 31 | 424 | 33947 | 90594045 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye irritation | 111.19 | 46.33 | 26 | 490 | 11292 | 42609527 |
| Amino acid level increased | 71.40 | 46.33 | 11 | 505 | 502 | 42620317 |
| Transplant rejection | 48.57 | 46.33 | 14 | 502 | 13574 | 42607245 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Amino acid level increased | 103.23 | 39.89 | 15 | 742 | 821 | 110587721 |
| Fibrosing colonopathy | 73.78 | 39.89 | 7 | 750 | 3 | 110588539 |
| Renal transplant | 57.38 | 39.89 | 11 | 746 | 3227 | 110585315 |
| Vomiting | 55.31 | 39.89 | 47 | 710 | 910628 | 109677914 |
| Transplant rejection | 48.20 | 39.89 | 14 | 743 | 24553 | 110563989 |
| Eye irritation | 43.94 | 39.89 | 14 | 743 | 33438 | 110555104 |
| Treatment noncompliance | 43.64 | 39.89 | 17 | 740 | 72973 | 110515569 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AA04 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Amino acids and derivatives |
| ATC | S01XA21 | SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals |
| FDA MoA | N0000175549 | Cystine Disulfide Reduction |
| MeSH PA | D065104 | Cystine Depleting Agents |
| FDA EPC | N0000187051 | Cystine Depleting Agent |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:66987 | radiation protective agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:176497 | geroprotector |
Related Drugs by ATC class:
A16AA Amino acids and derivatives 6 drugs
S01XA Other ophthalmologicals 24 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cystinosis | indication | 190681003 | |
| Depressive disorder | contraindication | 35489007 | |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Disorder of brain | contraindication | 81308009 | DOID:936 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Disorder of skin | contraindication | 95320005 | DOID:37 |
| Fracture of bone | contraindication | 125605004 | |
| Seizure disorder | contraindication | 128613002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Osteopenia | contraindication | 312894000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.54 | acidic |
| pKa2 | 9.41 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9192590 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9198882 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9925156 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9925157 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9925158 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9192590 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9198882 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9925156 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9925157 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9925158 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9192590 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9198882 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9925156 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9925157 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9925158 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9192590 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9198882 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9925156 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9925157 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 9925158 | Jan. 26, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8026284 | Sept. 22, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8026284 | Sept. 22, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 8026284 | Sept. 22, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 8026284 | Sept. 22, 2027 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10143665 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10328037 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10548859 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 25MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10905662 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10143665 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10328037 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10548859 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE | PROCYSBI | HORIZON | N203389 | April 30, 2013 | RX | CAPSULE, DELAYED RELEASE | ORAL | 10905662 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10143665 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10328037 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10548859 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 300MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10905662 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10143665 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10328037 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10548859 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| EQ 75MG BASE/PACKET | PROCYSBI | HORIZON | N213491 | Feb. 14, 2020 | RX | GRANULE, DELAYED RELEASE | ORAL | 10905662 | Aug. 16, 2036 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4020891 | VUID |
| N0000179403 | NUI |
| D03634 | KEGG_DRUG |
| 27761-19-9 | SECONDARY_CAS_RN |
| 1421468 | RXNORM |
| C0010648 | UMLSCUI |
| CHEBI:17141 | CHEBI |
| CHEMBL602 | ChEMBL_ID |
| 6058 | PUBCHEM_CID |
| DB00847 | DRUGBANK_ID |
| CHEMBL1256137 | ChEMBL_ID |
| CHEMBL1200577 | ChEMBL_ID |
| 7440 | IUPHAR_LIGAND_ID |
| 156-57-0 | SECONDARY_CAS_RN |
| 201127 | MMSL |
| 33306 | MMSL |
| 36492 | MMSL |
| 4523 | MMSL |
| 4954 | MMSL |
| d03794 | MMSL |
| 003510 | NDDF |
| 004750 | NDDF |
| 013719 | NDDF |
| 109109007 | SNOMEDCT_US |
| 109111003 | SNOMEDCT_US |
| 373457005 | SNOMEDCT_US |
| 442508008 | SNOMEDCT_US |
| D003543 | MESH_DESCRIPTOR_UI |
| DHL | PDB_CHEM_ID |
| SEA | PDB_CHEM_ID |
| 195 | INN_ID |
| 4020891 | VANDF |
| 4023983 | VANDF |
| 4032349 | VANDF |
| 5UX2SD1KE2 | UNII |
| 5UX2SD1KE2 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cystagon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9040 | CAPSULE | 50 mg | ORAL | NDA | 25 sections |
| Cystagon | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9045 | CAPSULE | 150 mg | ORAL | NDA | 25 sections |
| CYSTARAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54482-020 | SOLUTION | 6.50 mg | OPHTHALMIC | NDA | 25 sections |
| CYSTARAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54482-035 | SOLUTION | 6.50 mg | OPHTHALMIC | NDA | 25 sections |
| CYSTADROPS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-410 | SOLUTION | 3.50 mg | OPHTHALMIC | NDA | 25 sections |
| PROCYSBI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75987-100 | CAPSULE, DELAYED RELEASE PELLETS | 25 mg | ORAL | NDA | 29 sections |
| PROCYSBI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75987-101 | CAPSULE, DELAYED RELEASE PELLETS | 75 mg | ORAL | NDA | 29 sections |
| PROCYSBI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75987-140 | GRANULE, DELAYED RELEASE | 75 mg | ORAL | NDA | 29 sections |
| PROCYSBI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75987-145 | GRANULE, DELAYED RELEASE | 300 mg | ORAL | NDA | 29 sections |